Humacyte (NASDAQ:HUMA) Stock Price Breaks Above Fifty Day Moving Average – Here’s What Happened

Shares of Humacyte, Inc. (NASDAQ:HUMA) passed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $0.49 and traded as high as $0.5970. Humacyte shares last traded at $0.59, with a volume of 15,631,458 shares traded.

Humacyte News Summary

Here are the key news stories impacting Humacyte this week:

• Positive Sentiment: Humacyte reported a third-quarter loss of $0.06 per share, narrower than analysts’ expected loss of $0.10. Revenue of $1.03 million also topped estimates of about $0.77 million, though it remains small. Humacyte third-quarter results
• Positive Sentiment: Symvess sales reached $1.0 million in Q3, up 151% from Q2; October sales were $0.8 million. Management expects Q4 sales to at least double Q3, signaling continued commercial adoption. Humacyte sales and filing outlook
• Positive Sentiment: BTIG reaffirmed its Buy rating and $2 price target, reflecting a bullish analyst view, although the target is not a guarantee of future performance. BTIG rating information
• Positive Sentiment: The company said it plans to submit a supplemental biologics license application for dialysis use of Symvess in November. It also highlighted the start of a first-in-human study of its conduit for coronary bypass surgery, though clinical prospects remain uncertain. Humacyte coronary bypass study update
• Negative Sentiment: A report says Humacyte reached a $9 million deal to resolve a shareholder lawsuit. The settlement may create a financial cost even as it removes the case’s ongoing uncertainty. Shareholder lawsuit settlement

Analyst Upgrades and Downgrades

A number of brokerages have commented on HUMA. HC Wainwright reaffirmed a “buy” rating on shares of Humacyte in a research report on Friday, October 16th. Williams Trading set a $1.00 price target on shares of Humacyte in a report on Friday, October 16th. Wall Street Zen lowered shares of Humacyte from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Benchmark dropped their price objective on shares of Humacyte from $2.00 to $1.00 and set a “speculative buy” rating on the stock in a report on Thursday, August 13th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Humacyte in a research report on Friday, October 2nd. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $4.96.

Humacyte Stock Performance

The company has a market cap of $163.90 million, a price-to-earnings ratio of -1.20 and a beta of 2.64. The firm’s 50 day simple moving average is $0.49 and its 200-day simple moving average is $0.79. The company has a debt-to-equity ratio of 2.07, a quick ratio of 5.74 and a current ratio of 6.21.

Humacyte (NASDAQ:HUMA) last released its earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.05). The business had revenue of $0.41 million during the quarter, compared to analysts’ expectations of $1.04 million. Humacyte had a negative return on equity of 983.32% and a negative net margin of 4,556.29%. On average, sell-side analysts predict that Humacyte, Inc. will post -0.40 EPS for the current year.

Institutional Investors Weigh In On Humacyte

Several hedge funds and other institutional investors have recently made changes to their positions in HUMA. Beacon Pointe Advisors LLC acquired a new stake in shares of Humacyte in the second quarter valued at approximately $28,000. Bank of New York Mellon Corp purchased a new position in shares of Humacyte during the 2nd quarter worth $44,000. Sei Investments Co. purchased a new position in shares of Humacyte during the 1st quarter worth $56,000. Miramontes Capital LLC acquired a new position in shares of Humacyte during the 2nd quarter valued at about $85,000. Finally, LaSalle St. Investment Advisors LLC acquired a new position in shares of Humacyte during the 2nd quarter valued at about $89,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for use in regenerative medicine and vascular repair. The company’s platform is designed to create implantable, off-the-shelf tissues that can be stored and used when needed without requiring the collection of tissue from the patient. Its primary product is SYMVESS, an acellular tissue-engineered vessel intended to replace or repair damaged blood vessels. In December 2024, the U.S. Food and Drug Administration approved SYMVESS for use in the urgent treatment of extremity arterial injuries when emergency vascular reconstruction is required.